APEX1 and non-small cell lung carcinoma: In this context, the BER enzyme APE1 is considered a good predictive biomarker for lung cancer prognosis and treatment effect, since its overexpression is an important cause of poor chemotherapeutic efficacy in NSCLC patients [18, 20, 21, 29].